Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Melanoma 4Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solid Tumor 1Skin Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Inflammatory Breast Neoplasms 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Craniopharyngioma 1Cholangiocarcinoma 1Carcinosarcoma 1Brain Neoplasms 1

Interventions

pembrolizumab 15Paclitaxel 15Carboplatin 13Specimen Handling 6Biopsy 6durvalumab 5Magnetic Resonance Spectroscopy 5dostarlimab 4Taxes 4Surveys and Questionnaires 4Observation 4Letrozole 4Everolimus 4Cisplatin 4olaparib 3lenvatinib 3ceralasertib 3Doxorubicin 3sacituzumab govitecan 2pertuzumab 2copanlisib 2cabozantinib 2atezolizumab 2abemaciclib 2Trastuzumab 2Robotic Surgical Procedures 2Pemetrexed 2Nivolumab 2Metformin 2Megestrol Acetate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Endometrial Neoplasms × cobimetinib × Clear all
NCT05691504 2026-05-13

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

National Cancer Institute (NCI)

Phase 1 Active not recruiting
42 enrolled
GynecologicSarcoma

Carcinosarcoma, Fallopian Tube Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡